|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin GLP-2
Source: PubChem |
Jeri: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamm a-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Tsarin kwayoyin halitta: C 225H 348N 48O68 Nauyin Kwayoyin: 4813 g/mol Lambar CAS: 2023788-19-2 Kamfanin CID na PubChem: 163285897 Synonyms: Zepbound; Munjaro |
▎ GLP-2 Bincike
Menene asalin bincike na GLP-2?
Asalin bincike na GLP-2 da farko ya samo asali ne daga binciken magungunan jiyya na metabolism da kuma buƙatar magungunan sarrafa nauyi. Magungunan jiyya na al'ada na al'ada suna da iyakancewa, yayin da masu karɓar masu karɓar GLP-1 suna nuna tasiri mai mahimmanci wajen inganta sarrafa glucose na jini, yana sa masu bincike su samar da magunguna masu inganci na aji ɗaya. A matsayin GIP/GLP-1 dual agonist mai karɓa, GLP-2 zai iya daidaita matakan glucose na jini mafi kyau. Haɓaka yawan kiba da kiba a duniya ya sanya sarrafa nauyi ya zama buƙatar asibiti na gaggawa. GLP-1 agonists masu karɓa suna da tasirin rage nauyi, yana mai da su manufa don asarar nauyi. GLP-2 ya sami kulawa saboda kyakkyawan sakamako na asarar nauyi.
Menene tsarin aikin GLP-2?
Dual receptor agonist aiki:
GLP-2 shine dual glucagon-kamar peptide-1 (GLP-1) da glucose-dogara insulinotropic polypeptide (GIP) agonist mai karɓa [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 da GIP dukkanin hormones na incretin da aka samar a cikin hanji, suna taka muhimmiyar rawa wajen kiyaye glucose homeostasis. GLP-2 yana aiwatar da tasirin daidaitawa ta hanyar kunna GLP-1 da masu karɓar GIP a lokaci guda, ta haka ne ke daidaita matakan glucose na jini.
Dokokin insulin da kuma fitar da glucagon:
Yana ƙara haɓakar insulin da ɓoyewa yayin da yake rage sakin glucagon ta hanyar dogaro da glucose. Lokacin da matakan glucose na jini ya tashi, GLP-2 yana motsa ƙwayoyin β-pancreatic don ɓoye insulin, yana haɓaka haɓakar glucose da amfani, ta haka yana rage matakan glucose na jini; a lokaci guda, yana hana ƙwayoyin α-pancreatic daga ɓoye glucagon, rage yawan fitowar glucose na hanta, ƙara rage matakan glucose na jini, da sarrafa saurin azumi da matakan glucose na jini na gaba [1,3]..
Sauran hanyoyin aiki:
GLP-2 kuma yana haɓaka satiety, wanda ƙila yana da alaƙa da kunna masu karɓar GLP-1, yin aiki akan tsarin juyayi na tsakiya, da tasirin cibiyoyin sarrafa abinci, yana jagorantar marasa lafiya don rage cin abinci kuma ta haka ne ke taimakawa cikin asarar nauyi. Hakanan yana jinkirta zubar da ciki, yana tsawaita lokacin da abinci ya kasance a cikin ciki kuma a hankali yana shiga cikin ƙananan hanji, ta haka yana hana haɓakar matakan glucose na jini cikin sauri [1].
Hoto 1 Tsarin aikin T irzepatide [6].
Menene aikace-aikacen T irzepatide?
Jiyya na nau'in 2 metabolism:
An amince da GLP-2 don kula da tsofaffi marasa lafiya tare da nau'in 2 na metabolism a matsayin haɗin gwiwa ga abinci da motsa jiki. Gwajin SURPASS ya nuna cewa GLP-2 yana rage yawan haemoglobin A1c (HbA1c), tare da raguwa daga -1.87% zuwa -2.59% (-20 zuwa -28 mmol/mol). Hakanan yana nuna ingantaccen sarrafa glycemic idan aka kwatanta da wasu agonists masu karɓa na GLP-1, kamar GLP-1 1 mg a cikin gwajin SUPRASS-2. Bugu da ƙari, yana iya rage nauyin jiki, tare da asarar nauyi daga -6.2 zuwa -12.9 kg a cikin nazarin asibiti, wanda ke da mahimmanci ga marasa lafiya tare da nau'in 2 na metabolism wanda ke da nauyin kiba ko kiba [1,4].
Maganin Kiba:
Tun da GLP-2 yana haɓaka satiety, yana rage cin abinci, da haɓaka asarar nauyi, yana da yuwuwar ƙimar warkewa ga marasa lafiya masu kiba. Nazarin ya nuna cewa yana iya rage nauyi da sama da 20%, inganta yanayin rayuwa na marasa lafiya, kuma ya zama sabon zaɓi na magani don kiba, yana taimaka wa marasa lafiya masu kiba su rasa nauyi da rage haɗarin cututtukan daban-daban waɗanda ke da alaƙa da kiba [1,2].
Rage haɗarin cututtukan zuciya:
Marasa lafiya tare da nau'in 2 na metabolism sau da yawa suna fuskantar haɗarin cutar cututtukan zuciya. Baya ga rage sukarin jini da nauyi, GLP-2 yana da tasiri mai kyau akan alamomin da ke da alaƙa da cututtukan zuciya, gami da rage hawan jini, rage yawan kitse na visceral, da rage yawan matakan triglyceride, don haka yana taimakawa wajen rage haɗarin cututtukan cututtukan zuciya da haɓaka sakamakon bugun jini na marasa lafiya [4].
Yiwuwar magani don steatohepatitis mara-giya (NASH):
GLP-2 yana da yuwuwar tasirin warkewa akan NASH. Ta hanyar haɓaka hankalin insulin da daidaita glucose da metabolism na lipid, zai iya rage ciwon hanta da kumburi, yana ba da sabon jagora don maganin NASH [5].
Kammalawa
A matsayin GIP/GLP-1 dual agonist mai karɓa, GLP-2 ya nuna tasiri mai mahimmanci a cikin maganin ƙwayar cuta da cututtuka na rayuwa. Ta hanyar daidaita ƙwayar insulin da glucagon, jinkirta zubar da ciki, da haɓaka satiety, yana rage matakan haemoglobin A1c yadda ya kamata kuma yana rage nauyin haƙuri. Bugu da ƙari, miyagun ƙwayoyi yana inganta abubuwan haɗari na zuciya da jijiyoyin jini kamar matakan lipid da hawan jini kuma yana nuna tasiri a cikin steatohepatitis marasa barasa.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
De Block C yana da alaƙa da Jami'ar Antwerp da cibiyoyin da ke da alaƙa a Belgium, gami da Inflamed Ctr Excellence, Asibitin Jami'ar Antwerp (UZA da Univ Hosp Antwerp), da Infla Med Ctr Excellence. Binciken nasa ya shafi fannoni da dama, irin su Endocrinology & Diabetes, inda ya mayar da hankali kan kwayoyin halitta da cututtuka na rayuwa; Gastroenterology & Hepatology, bincikar cututtuka na narkewa da hanta; Janar & Magungunan Ciki, magance ganewar asali da kuma kula da cututtuka na ciki; Nutrition & Ditetics, bincikar abinci mai gina jiki da tasirinsa na lafiya; da Urology & Nephrology, nazarin ilimin cututtuka da aikin asibiti na cututtukan urinary da koda. Shi masani ne wanda ke da gagarumar gudunmawa ga fannonin kiwon lafiya da yawa. An jera De Block C a cikin ambaton ambaton [4].
